^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    inixaciclib (NUV-422)

    i
    Other names: NUV-422, NUV422, NUV 422
    Associations

    News

    Trials
    Company:
    Nuvation Bio
    Drug class:
    CDK4 inhibitor, CDK6 inhibitor, CDK2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors (clinicaltrials.gov)
    P1/2, N=72, Terminated, Nuvation Bio Inc. | N=269 --> 72 | Trial completion date: Dec 2023 --> Aug 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2023 --> Aug 2022; Sponsor decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CAST (Calpastatin)
    |
    HER-2 negative • IDH wild-type
    |
    inixaciclib (NUV-422)
    over2years
    Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Nuvation Bio Inc. | N=236 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • inixaciclib (NUV-422)
    over2years
    Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC (clinicaltrials.gov)
    P1/2, N=236, Suspended, Nuvation Bio Inc. | Initiation date: Apr 2022 --> Sep 2022 | Recruiting --> Suspended
    Trial initiation date • Trial suspension • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • inixaciclib (NUV-422)
    over2years
    Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors (clinicaltrials.gov)
    P1/2, N=269, Active, not recruiting, Nuvation Bio Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • CAST (Calpastatin)
    |
    HER-2 negative • IDH wild-type
    |
    inixaciclib (NUV-422)
    over2years
    Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC (clinicaltrials.gov)
    P1/2, N=236, Recruiting, Nuvation Bio Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • inixaciclib (NUV-422)
    almost3years
    Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC (clinicaltrials.gov)
    P1/2, N=236, Not yet recruiting, Nuvation Bio Inc.
    New P1/2 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • inixaciclib (NUV-422)
    over3years
    Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors (clinicaltrials.gov)
    P1/2, N=218, Recruiting, Nuvation Bio Inc. | N=80 --> 218
    Clinical • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    inixaciclib (NUV-422)